Sialic acid-containing glycoprotein receptors

Human sialic acid-containing glycoprotein receptors refer to a broad class of cell surface proteins modified with sialic acid (N-acetylneuraminic acid) residues, which serve as essential recognition sites for both endogenous and exogenous ligands. In the context of infectious diseases, these glycoproteins act as the primary attachment points for a variety of pathogens, most notably the influenza virus, which uses its hemagglutinin protein to bind specific sialic acid linkages on the host respiratory epithelium. Beyond their role in infection, these molecules serve as critical ligands for the Siglec (Sialic acid-binding immunoglobulin-type lectin) family of receptors, which play a central role in regulating immune cell activation and maintaining self-tolerance. From a therapeutic perspective, this target class is addressed by sialidases like DAS181, which strip sialic acids from the cell surface to prevent viral entry, or by drugs that target specific sialic acid-binding receptors like CD22 or CD33 to treat malignancies. The specific density and linkage of sialic acids on these receptors are key determinants of viral host range, tissue tropism, and immune signaling outcomes.

Other names

Sialic acid receptorsHost cell sialic acid receptorsSialylated glycoproteinsSialyl-glycoconjugatesSialic acid-binding lectin ligands

Therapeutic agents targeting these receptors primarily function by enzymatically removing sialic acid residues from the host cell surface to block pathogen attachment (e.g., DAS181), or by utilizing monoclonal antibodies and antibody-drug conjugates to target specific sialic acid-recognizing receptors such as Siglecs (e.g., CD22, CD33) or Selectins to modulate immune activity or deliver cytotoxic payloads.